ENHERTU® Granted Priority Review in the U.S. for Patien

Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data



Submission to be reviewed under FDA Real Time Oncology Review and Project Orbis



If approved,...

Related Keywords

United States , Japan , America , American , Daiichi Sankyo , Ken Takeshita , Susan Galbraith , European Society For Medical Oncology , Drug Administration , Merck Co Inc , Nasdaq , Astrazeneca , American Society Of Clinical Oncology , Clinical Development Program , Daiichi Sankyo Inc , National Cancer Institute , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Breakthrough Therapy Designation , Real Time Oncology Review , Project Orbis , Global Head , Executive Vice President , Medical Oncology , New England Journal , Clinical Oncology , Lung Disease , Breast Cancer , Metastatic Gastric Cancer , Absolute Neutrophil Count , Positive Metastatic Breast , Low Metastatic Breast , Reproductive Potential , Hepatic Impairment , Prescribing Information , Accessed January , Enhertu Marks First Targeted Therapy , Mutant Lung , Markets ,